Abstract：Objective To investigate the change in the serum level of follistatin-like protein 1(FSTL1) in children with chronic heart failure and its correlation with left ventricular remodeling.Methods A total of 45 children with chronic heart failure(CHF) between May 2014 and May 2015 were selected as the CHF group, among whom 21 had endocardial fibroelastosis(EFE) and 24 had dilated cardiomyopathy(DCM);another 30 healthy children were selected as the control group.Enzyme-linked immunosorbent assay was applied to measure the serum level of FSTL1.Radioimmunoassay was applied to measure N-terminal pro-brain natriuretic peptide, and echocardiography was applied to measure the indicators of left ventricular remodeling.The correlation between the serum level of FSTL1 and left ventricular remodeling was analyzed by Pearson correlation and Spearman's rank correlation analysis.Results Before treatment, the CHF group had a significantly higher serum level of FSTL1 than the control group(PPP=0.176).Serum level of FSTL1 was positively correlated with left ventricular enddiastolic diameter(r=0.485, P=0.001), left ventricular mass(r=0.322, P=0.031), left ventricular mass index(r=0.353, P=0.017), and N-terminal pro-brain natriuretic peptide(r=0.562 Pr=-0.436, P=0.003) and left ventricular minor axis decurtation rate(r=-0.436, P=0.003).Conclusions FSTL1 might take part in the left ventricular remodeling in children with CHF, and the serum level of FSTL1 can be used as an objective index for clinical diagnosis and severity assessment of CHF in children.
LI Bing-Lu,AN Jin-Dou,FENG Song et al. Change in serum follistatin-like protein 1 and its clinical significance in children with chronic heart failure[J]. CJCP, 2016, 18(2): 136-140.
Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure:recent advances in basic science[J]. Lancet, 2011, 378(9792):704-712.
[2]
Karayannis G, Triposkiadis F, Skoularigis J, et al. The emerging role of Galectin-3 and ST2 in heart failure:practical considerations and pitfalls using novel biomarker[J]. Curr Heart Fail Rep, 2013, 10(4):441-449.
[3]
Tülüce K, Yakar Tülüce S, Yavuzgil O, et al. The left atrial phasic functions and the relationship with plasma N-terminal pro-B-type natriuretic peptide levels and symptomatic states in patients with hypertrophic cardiomyopathy[J]. Anadolu Kardiyol Derg, 2014, 14(8):719-727.
[4]
Oshima Y, Ouchi N, Sato K, et al. Folliststin-like 1 is an Aktregulated cardioprotective factor that is secreted by the heart[J]. Circulation, 2008, 117(24):3099-3108.
[5]
Widera C, Giannitsis E, Kempf T, et al. Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome[J]. Clin Chem, 2012, 58(8):1233-1241.
[6]
Lara-Pezzi E, Felkin LE, Birks EJ, et al. Expression of follistatin-related genes is altered in heart failure[J]. Endocrinology, 2008, 149(11):5822-5827.
Ino T, Benson LN, Freedom RM, et al. Natural history and prognostic risk factors in endocardial fibroelastosis[J]. Am J Cardiol, 1988, 62(7):431-434.
[11]
Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy findings[J]. Am J Cardiol, 1986, 57(6):450-458.
[12]
Le Luduec JB, Condamine T, Louvet C, et al. An immunomodulatory role for follistatin-like 1 in heart allograft transplantation[J]. Am J Transplant, 2008, 8(11):2297-2306.
[13]
Ouchi N, Oshima Y, Ohashi K, et al. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism[J]. J Biol Chem, 2008, 283(47):32802-32811.
[14]
Ogura Y, Ouchi N, Ohashi K, et al. Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models[J]. Circulation, 2012, 126(14):1728-1738.
[15]
El-Armouche A, Ouchi N, Tanaka K, et al. Follistatin-like 1 in chronic systolic heart failure:a marker of left ventricular remodeling[J]. Circ Heart Fail, 2011, 4(5):621-627.
